Author:
Vago Luca,Dazzi Francesco
Abstract
AbstractRelapse represents one of the main unsolved issues in allogeneic HCT, prompting research on its underlying mechanisms. Growing evidence support the hypothesis that in many patients relapse is driven by immune changes in cancer cells and in the supporting microenvironment, abrogating the graft-versus-tumor effect.
Publisher
Springer International Publishing
Reference24 articles.
1. Bar-Natan M, Stroopinsky D, Luptakova K, et al. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017;176:929–38.
2. Biondi M, Tettamanti S, Galimberti S, Cerina B, Tomasoni C, Piazza R, Donsante S, Bido S, Perriello VM, Broccoli V, Doni A, Dazzi F, Mantovani A, Dotti G, Biondi A, Pievani A, Serafini M. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. Blood. 2023;141:2587–98.
3. Bronte V, Brandau S, Chen S-H, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
4. Cheung TS, Dazzi F. Mesenchymal-myeloid interaction in the regulation of immunity. Semin Immunol. 2018;35:59–68.
5. Christopher MJ, Petti AA, Rettig MP, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379(24):2330–41.